InTandem Capital Partners Closes Fund III with $715 Million in Capital Commitments

InTandem Capital Partners, LLC announced it has successfully concluded the final closing of InTandem Capital Partners Fund III, LP, garnering $715 million in total capital commitments, surpassing the original target of $650 million. The fund will maintain its focus on making control investments in North American payor, provider, and pharmaceutical services businesses.

Fund III has received investments from a diverse group of existing and new investors and has already completed its third platform deal in Adams Clinical, a multi-site clinical research management organization. The firm's Managing Partner, Elliot Cooperstone, expressed gratitude for the support and emphasized their commitment to delivering significant returns. 

InTandem Capital Partners is a private equity firm dedicated to investing in and fostering the growth of select healthcare services companies aligned with the Healthcare Quintuple Aim. The firm's team, consisting of former business executives and experienced investors, provides strategic, acquisition, and operating expertise to enhance the value and impact of portfolio companies, leveraging a network of industry executives for support.